The targeting of immunosuppressive mechanisms in hematological malignancies

Leukemia

Volumn 28, Issue 9, 2014, Pages 1784-1792

  Andersen, M H ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ENZYME; INDOEAMINE 2,3 DIOXYGENASE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TRYPTOPHAN; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEEDBACK SYSTEM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL;

ANTIGENS, CD274; CTLA-4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTORS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84908270619     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.108     Document Type: Review

References (84)

1. Heine A, Held SA, Bringmann A, Holderried TA, Brossart P. Immunomodulatory effects of anti-Angiogenic drugs. Leukemia. 2011; 25: 899-905
2. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia. 2003; 17: 1211-1262
3. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A., et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+ FoxP3+ regulatory T cells toward an antileukemia response. Leukemia. 2008; 22: 1007-1017
4. Giannopoulos K, Dmoszynska A, Kowal M, Rolinski J, Gostick E, Price DA., et al. Peptide vaccination elicits leukemia-Associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia. 2010; 24: 798-805
5. Fabricius D, Breckerbohm L, Vollmer A, Queudeville M, Eckhoff SM, Fulda S., et al. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia. 2011; 25: 1111-1121
6. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118: 4817-4828
7. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia. 2008; 22: 49-58
8. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008; 224: 166-182
9. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002; 3: 611-618
10. Perez-Garcia A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R., et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia. 2009; 23: 486-491
11. Zhong RK, Loken M, Lane TA, Ball ED. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy. 2006; 8: 3-12
12. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009; 113: 1581-1588
13. Fevery S, Billiau AD, Sprangers B, Rutgeerts O, Lenaerts C, Goebels J., et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia. 2007; 21: 1451-1459
14. Dong H, Zhu G, Tamada K, Chen L. B7-H1 a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5: 1365-1369
15. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y., et al. PD-1/.PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009; 23: 375-382
16. Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia. 2014; 28: 993-1000
17. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng Q-R., et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014; 28: 1280-1288
18. Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia. 2012; 26: 424-432
19. Kollgaard T, Petersen SL, Hadrup SR, Masmas TN, Seremet T, Andersen MH., et al. Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia. 2005; 19: 2273-2280
20. Ame-Thomas P, Le PJ, Yssel H, Caron G, Pangault C, Jean R., et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia. 2012; 26: 1053-1063
21. van deDonk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012; 26: 199-213
22. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A., et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013; 27: 464-472
23. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood. 2013; 121: 734-744
24. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS., et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004; 101: 17174-17179
25. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007; 104: 3360-3365
26. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/.programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13: 2151-2157
27. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-Associated malignancies. Clin Cancer Res. 2013; 19: 3462-3473
28. Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B., et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One. 2013; 8: e55818
29. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia. 2002; 16: 1069-1085
30. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465
31. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2453
32. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14: 3044-3051
33. Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK., et al. HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 2013; 73: 1674-1776
34. Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia. 2013; 27: 2251-2253
35. Mous R, Savage P, Remmerswaal EB, van Lier RA, Eldering E, van Oers MH. Redirection of CMV-specific CTL towards B-CLL via CD20-Targeted HLA/CMV complexes. Leukemia. 2006; 20: 1096-1102
36. Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T., et al. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia. 2011; 25: 932-938
37. Ahmad SM, Larsen SK, Svane IM, Andersen MH. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia. 2014; 28: 236-238
38. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264
39. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008; 322: 271-275
40. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006; 203: 1701-1711
41. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203: 1693-1700
42. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-Tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22: 531-562
43. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006; 212: 28-50
44. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N., et al. Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-beta Induction of Transcription Factor Foxp3. J Exp Med. 2003; 198: 1875-1886
45. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450: 566-569
46. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A., et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011; 6: e24671
47. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009; 15: 3325-3332
48. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106: 2018-2025
49. Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM., et al. Natural CD4(+) T-cell responses against indoleamine 2,3-dioxygenase. PLoS One. 2012; 7: e34568
50. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012; 72: 3439-3444
51. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007; 56: 641-648
52. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M., et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia. 2008; 22: 222-224
53. Giannopoulos K, Dmoszynska A, Kowal M, Wasik-Szczepanek E, Bojarska-Junak A, Rolinski J., et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia. 2009; 23: 1771-1778
54. Teng MW, Swann JB, von SB, Sharkey J, Zerafa N, McLaughlin N., et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res. 2010; 70: 2665-2674
55. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115: 3623-3633
56. Barnett BG, Ruter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ., et al. Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol. 2008; 622: 255-260
57. Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH., et al. Depletion of endogenous tumor-Associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009; 114: 3793-3802
58. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y., et al. Phase III placebocontrolled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010; 28: 1870-1877
59. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007; 67: 371-380
60. van ET, van Puijvelde GH, Foks AC, Habets KL, Bot I, Gilboa E., et al. Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. Atherosclerosis. 2010; 209: 74-80
61. Larsen SK, Munir S, Woetmann A, Froesig TM, Odum N, Svane IM., et al. Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia. 2013; 27: 2332-2340
62. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF., et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013; 123: 1999-2010
63. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010; 70: 3052-3061
64. Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S., et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006; 108: 2265-2274
65. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22: 633-642
66. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM., et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005; 310: 850-855
67. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007; 117: 1147-1154
68. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE., et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012; 2: 722-735
69. Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V., et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia. 2007; 21: 353-355
70. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2009; 113: 2394-2401
71. Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R., et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica. 2008; 93: 1894-1898
72. Hoshi M, Ito H, Fujigaki H, Takemura M, Takahashi T, Tomita E., et al. Changes in serum tryptophan catabolism as an indicator of disease activity in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2009; 50: 1372-1374
73. Lindstrom V, Aittoniemi J, Jylhava J, Eklund C, Hurme M, Paavonen T., et al. Indoleamine 2,3-dioxygenase activity and expression in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012; 12: 363-365
74. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010; 115: 3520-3530
75. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood. 2008; 111: 2152-2154
76. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. 2009; 9: 445-452
77. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC. thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011; 117: 2200-2210
78. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J., et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014; 20: 221-232
79. Yu J, Du W, Yan F, Wang Y, Li H, Cao S., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013; 190: 3783-3797
80. Mougiakakos D, Jitschin R, von BL, Poschke I, Gary R, Sundberg B., et al. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013; 27: 377-388
81. Bronte V, Zanovello P. Regulation of immune responses by L-Arginine metabolism. Nat Rev Immunol. 2005; 5: 641-654
82. Mussai F, De SC, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013; 122: 749-758
83. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314: 126-129
84. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11: 312-319